Caris Life Sciences,�Inc. (CAI) Business Profile

What it does

Caris Life Sciences is a precision medicine company focused initially on cancer. It analyzes molecular information from blood and tissue to help physicians understand a patient’s cancer and select treatments. It also supplies research and data services to biopharma companies and academic researchers. Founded in 2008, Caris is led by founder and chief executive David Dean Halbert.

Its MI Profile platform analyzes tumor tissue, including through MI Cancer Seek, a test approved by the FDA for certain companion diagnostic and tumor profiling uses. A companion diagnostic helps identify patients who may benefit from particular targeted treatments. Caris Assure analyzes blood samples for therapy selection and produces a report for oncologists. Its blood-based approach also separates some mutations arising in blood cells from tumor-derived mutations that could otherwise complicate results.

Caris combines sequencing with artificial intelligence and machine learning to interpret molecular data. Information generated through testing also goes into datasets used for research, including the identification of disease characteristics and potential drug targets. The company has performed sequencing on over 1,000,000 cases as of December 31, 2025.

Caris has since launched Caris Detect, an early-detection test, and Caris Assure Therapy Response Monitoring. It plans to introduce Caris Confirm for minimal residual disease testing, which looks for signs of cancer remaining or returning after treatment.

How it makes money

Caris generates revenue from molecular profiling services and pharma research and development services. It has one reportable segment. Physicians order its clinical profiling tests to inform cancer treatment, while biopharma companies use its profiling, data and bioinformatics capabilities for research and drug development.

Total revenue was $812.0 million in FY2025 and $275.4 million in the third quarter of 2026.

MI Profile tissue-based solutions have generated the majority of revenue to date. The platform includes MI Cancer Seek, which examines tumor tissue and produces a report for oncologists. Caris Assure provides blood-based profiling for therapy selection. Medicare reimburses Caris Assure for that use, and commercial payers provide varying levels of adoption or coverage. Reimbursement arrangements with individual payers determine prices for the tests they cover; differences in coverage and payment can affect the company’s overall average selling prices and margins.

The company also earns revenue through relationships with biopharma partners that use its platform for research and development. These services can include analysis of molecular data to identify disease characteristics and potential drug targets. Revenue recognition for projects can depend on the timing of activities under individual agreements.

Caris has expanded into products that can be used repeatedly over a patient’s care. Its monitoring test is intended for serial assessments of treatment response, while Caris Confirm is planned for post-treatment surveillance. Caris Detect is being sold directly to consumers on a self-pay basis. The company reports Detect revenue within pharma research and development services until it is material enough to disclose separately.

Customers and how it sells

Caris serves treating physicians, researchers and biopharma companies. Its precision oncology alliance connects cancer centers and research consortia that collaborate on research and standards for molecular testing. Named biopharma partners include Moderna, AbbVie, Xencor, Merck KGaA and Genentech.

Payers are also important to the business because they decide whether to cover tests and how much to reimburse. In FY2025, three payers accounted for 37.4%, 21.1% and 11.6% of revenue, respectively. Caris also depends on patients and providers using its tests and on its ability to bill and collect for services.

The United States accounted for $801.4 million of FY2025 revenue, or 98.7%. International revenue was $10.6 million in FY2025. MI Profile is available in all U.S. states and Puerto Rico. Caris Assure for therapy selection is available across the United States except New York, and in Puerto Rico. Internationally, Caris offers the tests through distributors and direct contracts with hospital systems where regulations permit.

The company also uses electronic medical records and portals for orders. More than 75% of orders were placed through those channels in the third quarter of 2026.

Suppliers and costs

Caris operates laboratory, research and development, and sales infrastructure to deliver its services. Its work requires scientists, engineers and laboratory technicians, as well as equipment, sample intake and storage, information systems, quality assurance and billing processes. The company also uses a menu of third-party immunohistochemical tests alongside its sequencing services.

The upgraded Caris Assure assay runs on Illumina’s NovaSeq X sequencing platform. Caris stocked inventory ahead of product launches and uses the same kits for Caris Detect and samples in the ACHIEVE 2 study. It has also invested in sequencing capacity to support Detect and other products designed for recurring use.

As testing volumes increase, Caris expects to add laboratory capacity, equipment, qualified labor and systems while maintaining turnaround times. It expects those efforts to increase capital expenditures and may increase the cost of services. The company also expects expenses to rise as it develops solutions, expands its organization and increases marketing. In the third quarter of 2026, operating expenses were $163 million.

Competitive position

Caris competes in several parts of precision oncology. In tissue-based profiling, it names Foundation Medicine and Tempus as competitors. In blood-based profiling for therapy selection, it also names Guardant Health. Early-detection competitors include Grail, Freenome, Guardant Health, Exact Sciences and Delfi Diagnostics. For minimal residual disease tracking and treatment monitoring, it names Natera, Guardant Health, Personalis and others.

Foundation Medicine, Guardant Health, Tempus, Natera and Personalis also compete with Caris in core biopharma services. Tempus and Foundation Medicine compete in genomic data and AI services. Some competitors may have greater financial resources, larger research teams or more established sales forces.

Caris’s potential defenses include its sequencing dataset, testing platforms, physician relationships and laboratory infrastructure. MI Cancer Seek has FDA approval for certain companion diagnostic and tumor profiling indications. The company has built a specialized commercial organization serving ordering physicians across major U.S. health systems, academic institutions and community settings.

Our reading: The dataset is a meaningful potential moat because it combines molecular information with clinical data and has been built through repeated testing, although rivals also offer genomic data services. Our reading: FDA approval and the physician channel support the clinical business, but they do not prevent competing tests or guarantee reimbursement. Our reading: Laboratory infrastructure helps Caris process samples, while maintaining and expanding that capacity requires continuing investment.

Growth opportunities

Caris plans to increase adoption of tissue-based profiling and expand its blood-based offerings beyond therapy selection. The company is developing uses across early detection, minimal residual disease tracking and treatment monitoring. It also plans to use data from existing solutions to develop additional products, expand its biopharma services and enrich its clinical and genomic datasets.

The company launched Caris Detect and is expanding it into additional markets. It has also launched Caris Assure Therapy Response Monitoring and plans to launch Caris Confirm for minimal residual disease testing in December. Caris plans to introduce minimal residual disease testing to select customers while working through reimbursement, rather than beginning with a broad launch. Its ACHIEVE 2 validation study had enrolled approximately 20,000 patients, and the company expects an interim readout in Q1 of 2027.

Clinical therapy selection volume was approximately 61,500 cases in the third quarter of 2026, up 21% year-over-year. Caris expects fourth-quarter therapy selection volume of approximately 65,000 cases. It also expects approximately $1.04 billion to $1.05 billion in full-year 2026 revenue.

Beyond oncology, Caris plans to explore applications for its innovation platform in chronic diseases, including cardiology, neurology and metabolic conditions. Commercializing new uses can require development, validation, regulatory work and payer coverage.

Structural risks

• Coverage and reimbursement: Payers make independent coverage and payment decisions. Limited coverage or inadequate reimbursement could constrain clinical case volume and revenue. Caris is still working through reimbursement for its monitoring and minimal residual disease offerings.

• Competition and adoption: Precision oncology is highly competitive and changes rapidly. New or existing tests must gain acceptance among clinicians, patients and payers; competing products and differences in evidence requirements can affect adoption.

• Development and regulation: New tests may require validation studies, clinical trials, regulatory approvals or other authorizations. Caris cannot be certain when or whether its in-development uses will become commercially available.

• Operational capacity: Rising demand requires more sample processing, storage, laboratory capacity, equipment and qualified labor. If Caris cannot expand its capabilities while maintaining turnaround times, revenue may be affected.

• Legal and data exposure: Government investigations, payer audits, recoupment efforts and litigation can affect financial results. Caris also handles health information and relies on information systems, including third-party services; a cybersecurity incident could cause data loss or disclosure, litigation and regulatory investigations.

• Financial results: Caris incurred a net loss of $68.1 million in FY2025 and may incur net losses in the near future as it invests in new solutions, organizational expansion and marketing.

Bottom line

Our reading

Caris combines a clinical testing business with research services that draw on data generated through molecular profiling. Our reading: Its established tissue platform, dataset and physician relationships provide a base for expansion, but payer coverage and laboratory capacity remain important constraints. Its newer detection and monitoring products also bring validation, reimbursement and commercialization risks alongside their potential for repeat testing.